Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

direct rx - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 1.5 mg - allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. dermatologic diseases bullous dermatitis herpetiformis, exfoliative erythroderma, mycisis fungoides, pemphigus, and severe erythema multiforme (stevens-johnson syndrome). endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. gastrointestinal diseases to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. hematologic disorders acquired (autoimmune) hemolytic anemia, congen

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 0.75 mg - control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (stevens-johnson syndrome). primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (diamond-blackfan anemia), idiopathic thrombocytopenic purpura in adul

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

ecr pharmaceuticals - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 1.5 mg - allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. dermatologic diseases bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (stevens-johnson syndrome). endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. gastrointestinal diseases to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. hematologic disorders acquired (autoimmune) h

Kanāda - angļu - Health Canada

omega laboratories limited - dexamethasone phosphate (dexamethasone sodium phosphate) - solution - 10mg - dexamethasone phosphate (dexamethasone sodium phosphate) 10mg - adrenals

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

vedco, inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 2 mg in 1 ml - dexamethasone injection 2 mg/ml is indcated for  the treatment of primary bovine ketosis an as an anti-inflammatory agent in the bovine and equine. as supportive therapy, dexamethasone injection 2 mg/ml may be used in the management of vairious rheumatic, allergic dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids.  dexamethasone injection 2 mg/ml may be used intravenously as supportive therapy when an immeidate hormonal response is required. bovine ketosis dexamethasone injection 2 mg/ml is offered for the treatment of primary ktosis.  the gluconeogenic effects of dexamethasone injection 2 mg/ml, when administered intramuscularyly, are generally noted within the first 5 to 12 hours.  when dexamethasone injection 2 mg/ml is used intravenously, the effects may be noted sooner.  blood sugar levels rise to normal levels repidly and genreally rise to above normal levels within 12 to 24 hours.  acetone bodies are reduce to normal concentrations usually witnin 24 hours.  th

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

clipper distributing company, llc - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 2 mg in 1 ml - dexamethasone injection 2 mg/ml is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine. as supportive therapy, dexamethasone injection 2 mg/ml may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids. dexamethasone injection 2 mg/ml may be used intravenously as supportive therapy when an immediate hormonal response is required. bovine ketosis dexamethasone injection 2 mg/ml is offered for the treatment of primary ketosis. the gluconeogenic effects of dexamethasone injection 2 mg/ml, when administered intramuscularly, are generally noted within the first 6 to 12 hours. when dexamethasone injection 2 mg/ml is used intravenously, the effects may be noted sooner. blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours. acetone bodies are reduced to normal concentrations usually within 24 hours. the p

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

vettek - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 2 mg in 1 ml - dexamethasone injection 2 mg/ml is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine. as supportive therapy, dexamethasone injection 2 mg/ml may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids. dexamethasone injection 2 mg/ml may be used intravenously as supportive therapy when an immediate hormonal response is required. bovine ketosis dexamethasone injection 2 mg/ml is offered for the treatment of primary ketosis. the gluconeogenic effects of dexamethasone injection 2 mg/ml, when administered intramuscularly, are generally noted within the first 6 to 12 hours. when dexamethasone injection 2 mg/ml is used intravenously, the effects may be noted sooner. blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours. acetone bodies are reduced to normal concentrations usually within 24 hours. the

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

fresenius kabi usa, llc - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 4 mg in 1 ml - - intravenous or intramuscular administration. when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: endocrine disorders. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - dexamethasone - oral tablet - 2mg

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - dexamethasone - oral tablet - 2mg